FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004998033> ?p ?o ?g. }

• W2004998033 endingPage "373" @default.
• W2004998033 startingPage "366" @default.
• W2004998033 abstract "Background Some patients with acute VTE who may previously have been exposed to heparin products have unrecognized antibodies implicated in heparin-induced thrombocytopenia (HIT). Antibody prevalence and patient consequences upon exposure to heparin, low-molecular-weight heparin, and fondaparinux are uncertain. Methods In this secondary analysis, we tested patients in the Matisse VTE studies at study entry for heparin-dependent antibodies and further tested patients with enzyme-linked immunosorbent assay (ELISA)-positive results for platelet-activating antibodies. We compared the risk of HIT (> 50% fall in platelet count, heparin-dependent antibodies, no contradicting features) between patients treated with heparin (either unfractionated or low molecular weight [enoxaparin]) vs those who received fondaparinux. Comparison groups for thrombocytopenia occurrence comprised patients with ELISA-positive, platelet-activating, antibody-positive results; ELISA-positive, but platelet-activating antibody-negative results; and randomly selected antibody-negative results. Results A total of 127 of 3,994 patients (3.2%) had ELISA-positive results at baseline, but only 14 (0.4%; 95% CI, 0.2%-0.6%) had platelet-activating antibodies. Among these 14, four treated with unfractionated or low-molecular-weight heparin developed HIT compared with zero of 10 fondaparinux-treated patients (OR, 95; 95% CI, 8-1,123; P < .001). This frequency (four of four, 100%) significantly differed from that of both heparin-treated patients whose results were ELISA positive but platelet-activating antibody negative and from heparin-treated antibody-negative control subjects (zero of 15 and zero of 27, respectively; P < .001 for both). Conclusions Of patients with VTE, 0.4% had pathologic platelet-activating heparin-dependent antibodies rather than the 3.2% detected by the recommended cutoff of the commercial ELISA. Among study patients with acute VTE who had platelet-activating antibodies, treatment with fondaparinux reduced the risk of precipitating rapid-onset HIT. Some patients with acute VTE who may previously have been exposed to heparin products have unrecognized antibodies implicated in heparin-induced thrombocytopenia (HIT). Antibody prevalence and patient consequences upon exposure to heparin, low-molecular-weight heparin, and fondaparinux are uncertain. In this secondary analysis, we tested patients in the Matisse VTE studies at study entry for heparin-dependent antibodies and further tested patients with enzyme-linked immunosorbent assay (ELISA)-positive results for platelet-activating antibodies. We compared the risk of HIT (> 50% fall in platelet count, heparin-dependent antibodies, no contradicting features) between patients treated with heparin (either unfractionated or low molecular weight [enoxaparin]) vs those who received fondaparinux. Comparison groups for thrombocytopenia occurrence comprised patients with ELISA-positive, platelet-activating, antibody-positive results; ELISA-positive, but platelet-activating antibody-negative results; and randomly selected antibody-negative results. A total of 127 of 3,994 patients (3.2%) had ELISA-positive results at baseline, but only 14 (0.4%; 95% CI, 0.2%-0.6%) had platelet-activating antibodies. Among these 14, four treated with unfractionated or low-molecular-weight heparin developed HIT compared with zero of 10 fondaparinux-treated patients (OR, 95; 95% CI, 8-1,123; P < .001). This frequency (four of four, 100%) significantly differed from that of both heparin-treated patients whose results were ELISA positive but platelet-activating antibody negative and from heparin-treated antibody-negative control subjects (zero of 15 and zero of 27, respectively; P < .001 for both). Of patients with VTE, 0.4% had pathologic platelet-activating heparin-dependent antibodies rather than the 3.2% detected by the recommended cutoff of the commercial ELISA. Among study patients with acute VTE who had platelet-activating antibodies, treatment with fondaparinux reduced the risk of precipitating rapid-onset HIT." @default.
• W2004998033 created "2016-06-24" @default.
• W2004998033 creator A5012151994 @default.
• W2004998033 creator A5025282606 @default.
• W2004998033 creator A5039204383 @default.
• W2004998033 creator A5042290277 @default.
• W2004998033 creator A5071135543 @default.
• W2004998033 creator A5071835932 @default.
• W2004998033 creator A5075115394 @default.
• W2004998033 creator A5077272475 @default.
• W2004998033 creator A5084098960 @default.
• W2004998033 creator A5084922482 @default.
• W2004998033 date "2011-08-01" @default.
• W2004998033 modified "2023-10-12" @default.
• W2004998033 title "Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE" @default.
• W2004998033 cites W108425301 @default.
• W2004998033 cites W1967814713 @default.
• W2004998033 cites W1976543113 @default.
• W2004998033 cites W1976659388 @default.
• W2004998033 cites W2000389681 @default.
• W2004998033 cites W201640808 @default.
• W2004998033 cites W2022932023 @default.
• W2004998033 cites W2034150101 @default.
• W2004998033 cites W2040920500 @default.
• W2004998033 cites W2058115183 @default.
• W2004998033 cites W2065460960 @default.
• W2004998033 cites W2068992029 @default.
• W2004998033 cites W2075407205 @default.
• W2004998033 cites W2076599358 @default.
• W2004998033 cites W2098653559 @default.
• W2004998033 cites W2105079657 @default.
• W2004998033 cites W2112564023 @default.
• W2004998033 cites W2134908914 @default.
• W2004998033 cites W2137037994 @default.
• W2004998033 cites W2150567223 @default.
• W2004998033 cites W2150922204 @default.
• W2004998033 cites W2156320702 @default.
• W2004998033 cites W2159553511 @default.
• W2004998033 cites W2253704389 @default.
• W2004998033 cites W2316071283 @default.
• W2004998033 cites W2333983635 @default.
• W2004998033 doi "https://doi.org/10.1378/chest.10-1599" @default.
• W2004998033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21393394" @default.
• W2004998033 hasPublicationYear "2011" @default.
• W2004998033 type Work @default.
• W2004998033 sameAs 2004998033 @default.
• W2004998033 citedByCount "67" @default.
• W2004998033 countsByYear W20049980332012 @default.
• W2004998033 countsByYear W20049980332013 @default.
• W2004998033 countsByYear W20049980332014 @default.
• W2004998033 countsByYear W20049980332015 @default.
• W2004998033 countsByYear W20049980332016 @default.
• W2004998033 countsByYear W20049980332017 @default.
• W2004998033 countsByYear W20049980332018 @default.
• W2004998033 countsByYear W20049980332019 @default.
• W2004998033 countsByYear W20049980332020 @default.
• W2004998033 countsByYear W20049980332021 @default.
• W2004998033 countsByYear W20049980332022 @default.
• W2004998033 crossrefType "journal-article" @default.
• W2004998033 hasAuthorship W2004998033A5012151994 @default.
• W2004998033 hasAuthorship W2004998033A5025282606 @default.
• W2004998033 hasAuthorship W2004998033A5039204383 @default.
• W2004998033 hasAuthorship W2004998033A5042290277 @default.
• W2004998033 hasAuthorship W2004998033A5071135543 @default.
• W2004998033 hasAuthorship W2004998033A5071835932 @default.
• W2004998033 hasAuthorship W2004998033A5075115394 @default.
• W2004998033 hasAuthorship W2004998033A5077272475 @default.
• W2004998033 hasAuthorship W2004998033A5084098960 @default.
• W2004998033 hasAuthorship W2004998033A5084922482 @default.
• W2004998033 hasConcept C126322002 @default.
• W2004998033 hasConcept C159654299 @default.
• W2004998033 hasConcept C203014093 @default.
• W2004998033 hasConcept C2776472838 @default.
• W2004998033 hasConcept C2776877702 @default.
• W2004998033 hasConcept C2776884760 @default.
• W2004998033 hasConcept C2777557582 @default.
• W2004998033 hasConcept C2780868729 @default.
• W2004998033 hasConcept C2991741193 @default.
• W2004998033 hasConcept C71924100 @default.
• W2004998033 hasConcept C89560881 @default.
• W2004998033 hasConcept C90924648 @default.
• W2004998033 hasConceptScore W2004998033C126322002 @default.
• W2004998033 hasConceptScore W2004998033C159654299 @default.
• W2004998033 hasConceptScore W2004998033C203014093 @default.
• W2004998033 hasConceptScore W2004998033C2776472838 @default.
• W2004998033 hasConceptScore W2004998033C2776877702 @default.
• W2004998033 hasConceptScore W2004998033C2776884760 @default.
• W2004998033 hasConceptScore W2004998033C2777557582 @default.
• W2004998033 hasConceptScore W2004998033C2780868729 @default.
• W2004998033 hasConceptScore W2004998033C2991741193 @default.
• W2004998033 hasConceptScore W2004998033C71924100 @default.
• W2004998033 hasConceptScore W2004998033C89560881 @default.
• W2004998033 hasConceptScore W2004998033C90924648 @default.
• W2004998033 hasIssue "2" @default.
• W2004998033 hasLocation W20049980331 @default.
• W2004998033 hasLocation W20049980332 @default.
• W2004998033 hasOpenAccess W2004998033 @default.
• W2004998033 hasPrimaryLocation W20049980331 @default.

• next